Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia (Q34146996)

31 July 2017

title

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia (English)

1 reference

31 July 2017

1 reference

lymphoblastic leukemia

1 reference

13

Hagop M Kantarjian

1 reference

31 July 2017

5

Stefan Faderl

1 reference

31 July 2017

7

Srdan Verstovsek

1 reference

31 July 2017

11

William Wierda

1 reference

31 July 2017

4

Jorge Cortes

1 reference

31 July 2017

2

Susan O'Brien

1 reference

31 July 2017

9

Sherry Pierce

1 reference

31 July 2017

Guillermo Garcia-Manero

series ordinal

6

object named as

Guillermo Garcia-Manero

1 reference

31 July 2017

12

Michael J Keating

1 reference

31 July 2017

3

Jeffrey L Jorgensen

1 reference

31 July 2017

Deborah A Thomas

1

1 reference

31 July 2017

Charles Koller

series ordinal

8

1 reference

31 July 2017

Yang Huh

series ordinal

10

1 reference

31 July 2017

language of work or name

English

0 references

publication date

14 August 2008

1 reference

31 July 2017

1 reference

31 July 2017

volume

113

1 reference

31 July 2017

issue

25

1 reference

31 July 2017

page(s)

6330-6337

1 reference

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943753

Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943753

Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943753

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943753

Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943753

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943753

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943753

Rituximab in relapsed or refractory hairy cell leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943753

Levels of expression of CD19 and CD20 in chronic B cell leukaemias

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943753

Evaluation of survival data and two new rank order statistics arising in its consideration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943753

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943753

The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943753

Rituximab in indolent lymphoma: the single-agent pivotal trial

28 October 2018

1 reference

12 December 2020

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

12 December 2020

Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia

1 reference

12 December 2020

Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study

1 reference

12 December 2020

10.1182/BLOOD-2008-04-151860

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference